Drug
Pidotimod
Pidotimod: highest development phase Post-Market, developed by Almirall. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Almirall
Trials
| Drug | Phase | Indication |
|---|---|---|
| Pidotimod NCT04322669 | Post-Market | Recurrent Respiratory Tract Infections |
Latest
No recent events.
Follow Pidotimod on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.